147 related articles for article (PubMed ID: 34453478)
21. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
22. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.
Tokarsky EJ; Crow JC; Guenther LM; Sherman J; Taslim C; Alexe G; Pishas KI; Rask G; Justis BS; Kasumova A; Stegmaier K; Lessnick SL; Theisen ER
Mol Cancer Res; 2022 Jul; 20(7):1035-1046. PubMed ID: 35298000
[TBL] [Abstract][Full Text] [Related]
24. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
[TBL] [Abstract][Full Text] [Related]
25. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
[TBL] [Abstract][Full Text] [Related]
26. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
[TBL] [Abstract][Full Text] [Related]
27. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc.
Nagasaka M; Tsuzuki K; Ozeki Y; Tokugawa M; Ohoka N; Inoue Y; Hayashi H
Biol Pharm Bull; 2019; 42(3):481-488. PubMed ID: 30828079
[TBL] [Abstract][Full Text] [Related]
28. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
30. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
Kurmasheva RT; Reynolds CP; Kang MH; Allievi C; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 May; 61(5):922-4. PubMed ID: 24166988
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.
Metzger E; Imhof A; Patel D; Kahl P; Hoffmeyer K; Friedrichs N; Müller JM; Greschik H; Kirfel J; Ji S; Kunowska N; Beisenherz-Huss C; Günther T; Buettner R; Schüle R
Nature; 2010 Apr; 464(7289):792-6. PubMed ID: 20228790
[TBL] [Abstract][Full Text] [Related]
32. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
33. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
[TBL] [Abstract][Full Text] [Related]
34. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
Sonnemann J; Zimmermann M; Marx C; Ebert F; Becker S; Lauterjung ML; Beck JF
Br J Haematol; 2018 Nov; 183(3):494-497. PubMed ID: 29205263
[No Abstract] [Full Text] [Related]
35. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
36. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
[TBL] [Abstract][Full Text] [Related]
37. Germline Lysine-Specific Demethylase 1 (
Wei X; Calvo-Vidal MN; Chen S; Wu G; Revuelta MV; Sun J; Zhang J; Walsh MF; Nichols KE; Joseph V; Snyder C; Vachon CM; McKay JD; Wang SP; Jayabalan DS; Jacobs LM; Becirovic D; Waller RG; Artomov M; Viale A; Patel J; Phillip J; Chen-Kiang S; Curtin K; Salama M; Atanackovic D; Niesvizky R; Landgren O; Slager SL; Godley LA; Churpek J; Garber JE; Anderson KC; Daly MJ; Roeder RG; Dumontet C; Lynch HT; Mullighan CG; Camp NJ; Offit K; Klein RJ; Yu H; Cerchietti L; Lipkin SM
Cancer Res; 2018 May; 78(10):2747-2759. PubMed ID: 29559475
[TBL] [Abstract][Full Text] [Related]
38. Initial testing of cisplatin by the pediatric preclinical testing program.
Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
[TBL] [Abstract][Full Text] [Related]
39. Machine-Learning-Enabled Virtual Screening for Inhibitors of Lysine-Specific Histone Demethylase 1.
Zhou J; Wu S; Lee BG; Chen T; He Z; Lei Y; Tang B; Hirst JD
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946572
[TBL] [Abstract][Full Text] [Related]
40. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
